Author: Arring, Noel ; Page, Seth J ; Kachnic, Lisa A ; Goodman, Judie R ; Pugh, Stephanie L ; Littell, Ramey D ; Razaq, Wajeeha ; Borges, Monica ; Siddique, Shahzad ; Rowland, Kendrith M ; Carter, Jeanne ; Barton, Debra L

AbstractBackgroundFemale cancer survivors often experience estrogen-deprivation symptoms, which may lead to decreases in sexual desire, vulvovaginal health (lubrication, dryness, discomfort), and sexual satisfaction. Interventions are needed to address these concerns.AimThe objective of this secondary analysis was to determine if women with higher (better) scores on the Female Sexual Function Index (FSFI) lubrication and pain subscales reported higher desire scores based on treatment with bupropion vs placebo.MethodsParticipants were part of NRG Oncology’s NRG-CC004 (NCT03180294), a randomized placebo-controlled clinical trial evaluating bupropion (150 vs 300 mg) to improve sexual desire in survivors of breast or gynecologic cancer. All participants with baseline data from the FSFI lubrication, pain, and desire subscales with 5- and/or 9-week data were analyzed. The FSFI subscale scores were correlated using Spearman correlation coefficients. Logistic regression was used to determine associations between FSFI desire and other FSFI subscales while accounting for treatment arm and other covariates.OutcomesThe primary outcome of NRG Oncology’s NRG-CC004 (NCT03180294) randomized phase II dose-finding trial was change from baseline to 9 weeks on the FSFI desire subscale score. Similar to the parent study, the primary outcome for this ancillary data study was the FSFI desire subscale score at 5 and 9 weeks.ResultsOverall, 230 participants completed the FSFI at baseline and 189 at 9 weeks. The strongest correlations were between lubrication and pain at baseline (all participants, rho = 0.77; bupropion arms, rho = 0.82), week 5 (all participants, rho = 0.71; bupropion arms, rho = 0.68), and week 9 (all participants, rho = 0.75; bupropion arms, rho = 0.78), and the weakest correlations were between desire and pain. In patients in the treatment arms there were no interactions between lubrication or pain.The impact of various covariates on the FSFI score for desire at 9 weeks demonstrated that participants of non-White race (odds ratio [OR], 0.42; 95% CI, 0.21-0.81; P = .010), with a high lubrication score (OR, 0.36; 95% CI, 0.21-0.61; P = .0002), with a high pain score (less pain) (OR, 0.50; 95% CI, 0.29-0.87; P = .014), or with prior pelvic surgery (OR, 0.38; 95% CI, 0.23-0.63; P = .0002) had lower odds of having low desire.Clinical ImplicationsAcute estrogen-deprivation symptoms should be addressed prior to sexual desire intervention.Strengths and LimitationsThis secondary analysis was not powered to examine all variables.ConclusionLubrication and pain were predictors of low desire. Therefore, vulvovaginal atrophy and associated genitourinary symptoms of menopause such as vaginal dryness and dyspareunia should be addressed prior to or in parallel with interventions for sexual desire.

Natural Product Research

Phytochemical investigation and spectral characterization of isolated compounds from Pyracantha crenulata (D. Don) M. Roem (syn. Crataegus crenulata Roxb) leaves: evaluation of antioxidant activity and molecular docking analysis

Article

Author: Murad Ghalib, Raza ; Malik, Abdul ; Kumar, Avadhesh ; Nami, Shahab A.A. ; Ali Khan, Azmat ; Alam, Mahboob ; Parveen, Mehtab

Pyracantha crenulata (D. Don) M. Roem (syn. Crataegus crenulata Roxb.) is an evergreen shrub in the Rosaceae family, notable for its chemical diversity and biological potential. This study isolates and characterises six compounds (Cc-1 to Cc-6), including four new ones, using repeated column chromatography. Structural elucidation employed IR, UV-vis, 1H and 13 C NMR, and mass spectrometry. The DPPH assay was used to test the antioxidant activity in vitro. Compounds Cc-4, Cc-2, Cc-1, and Cc-5 had IC50 values of 15.734 μg/ml, 51.422 μg/ml, 62.864 μg/ml, and 71.622 μg/ml, in that order. Quantitative phytochemical analysis revealed flavonoid content (22.81 mg/g), tannin content (385.15 mg/g), and total phenolic content (128.78 mg/g). Human cyclin-dependent kinase 2 (CDK2) (PDB ID: 1hck) docked with compound Cc-4, which demonstrated strong antioxidant activity and revealed significant non-bonding interactions. The pkCSM and SwissADME analyses suggested promising drug-like properties for Cc-4, supported by BOILED-Egg diagrams highlighting its therapeutic potential.

100 Deals associated with CC-004

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Preclinical	CN	Chupu Chuang (Wuhan) Pharmaceutical Technology Co., Ltd.	16 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

CC-004

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation